INSIGHTS ON LIQUID DOSE MANUFACTURING

LIQUID DOSE MANUFACTURING SOLUTIONS

  • AST aseptic filling products address the unique processing requirements of biologics manufacturing to gently care for biologic products during the fill-finish process. Their highly accurate peristaltic dosing system uses single-use pharmaceutical grade tubing that has been optimized to keep shear stress to an absolute minimum. When exiting the fluid path through the filling needle, the motion control system maintains the fill needle within the container and slowly rises as the product is being dispensed to minimize splashing and foaming that could introduce stress to the product. Temperature controlled filling is also possible with the ASEPTiCell® and GENiSYS® systems. AST has experience dosing products at temperatures as low as 3°C.

  • Used M&O Perry inline liquid vial filler, Model P-1510, stainless steel construction, speeds from 35-45 vials/minute, set up with filling, plug inserting and capping stations, Flexicon peristaltic fill pump, V change conveyor, change parts for 13 and 20mm plugs/caps with bowl feeders, vial infeed rotary table, and discharge rotary table, serial# P-888, built 2006.

  • Accelerate single-cell and low-volume workflows with high precision, fast setup, and surfactant-free dispensing that delivers reproducible results and flexible performance across cell types and reagents.

  • After conducting extensive research on the chemical performance of the glass vial inner surface and the glass forming process parameters, Stevanato Group added SG LDP Vials to its portfolio. These containers are specifically designed to minimize the formation of surface inhomogeneities.

  • Cell and gene therapies have increased in popularity in recent years, and thanks to their ability to provide one-time treatments these therapies will play a significant role in treating some of the world's most challenging diseases. These drug products treat patients afflicted with genetic disorders and cancers by targeting the source of disease and altering its genetic makeup to eliminate its cause or symptoms. These therapies are expensive and complex and have been proven effective in numerous cases, but they present a challenge in producing them at scale and at a reasonable cost.